Agree, these guys will be no slouches in getting traction with...

Agree, these guys will be no slouches in getting traction with the company this year. This is the trans formative year we will see the value for shareholders increase.

Last year was all about getting the pieces of the puzzle together, this year is all about execution as we saw late last year with a flurry of announcements, i do not expect them to stop IMO

Plenty of news flow to come this quarter.

A 10 cent valuation equates to roughly $60 mil market cap.

If we compare the likes of RHT with there recently approved FDA approval ( which we already have for SphygmoCor )

Then there is no reason we should not be at least 6-7 cents.

But given what else we have on the radar as pointed out in the company overview, there is just far to much potential here for it to be sitting around current levels

$50-60 mil market cap seems reasonable. IMO